Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Kohl's Corporation (KSS) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Kohl's CorporationTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Kohl's Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.42 (market cap $505.73M), while Kohl's Corporation trades at $18.99 (market cap $2.10B). The key difference: Kohl's Corporation is far larger — about 4.2× Ginkgo Bioworks Holdings Inc's market cap, and Kohl's Corporation pays a 2.7% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

DNAKSS
Market Cap
$505.73M$2.10B
Sector
HealthConsumer Cyclical
52-Week High
$16.14$24.71
52-Week Low
$5.48$11.72
Enterprise Value
$607.68M$8.20B
Dividend Yield
2.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Kohl's Corporation

Kohl's (KSS) trades at $18.96, down 0.42% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows low valuation multiples (P/E of 7.77, P/S of 0.14) amid declining revenue, which fell to $16.22B in 2025. Recent Q1 2026 earnings beat expectations, and the company announced a $0.13 dividend for June 2026, alongside leadership changes including a new COO appointment in September 2026.

The outlook is mixed: low valuations and earnings beats offer value, but persistent sales declines and thin net margins near 1.77% pose risks. Analyst consensus is cautious with a $16.75 price target below the current price, reflecting concerns over competitive pressures and cash flow volatility. Investors should weigh cost-cutting progress against macroeconomic headwinds in retail.

Returns comparison

Trailing returns across standard periods

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About Kohl's Corporation

Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.

Read more on KSS